AEON Biopharma (AEON) Competitors $0.69 +0.02 (+2.97%) (As of 09/20/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsTrends AEON vs. ASRT, ALXO, ASMB, FBLG, VSTM, SGMT, CASI, PDSB, PYRGF, and CYTTShould you be buying AEON Biopharma stock or one of its competitors? The main competitors of AEON Biopharma include Assertio (ASRT), ALX Oncology (ALXO), Assembly Biosciences (ASMB), FibroBiologics (FBLG), Verastem (VSTM), Sagimet Biosciences (SGMT), CASI Pharmaceuticals (CASI), PDS Biotechnology (PDSB), PyroGenesis Canada (PYRGF), and Cyteir Therapeutics (CYTT). These companies are all part of the "pharmaceutical preparations" industry. AEON Biopharma vs. Assertio ALX Oncology Assembly Biosciences FibroBiologics Verastem Sagimet Biosciences CASI Pharmaceuticals PDS Biotechnology PyroGenesis Canada Cyteir Therapeutics Assertio (NASDAQ:ASRT) and AEON Biopharma (NASDAQ:AEON) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, risk, earnings, valuation, community ranking, analyst recommendations, media sentiment, dividends and institutional ownership. Does the media refer more to ASRT or AEON? In the previous week, Assertio had 2 more articles in the media than AEON Biopharma. MarketBeat recorded 2 mentions for Assertio and 0 mentions for AEON Biopharma. Assertio's average media sentiment score of 0.67 beat AEON Biopharma's score of 0.00 indicating that Assertio is being referred to more favorably in the media. Company Overall Sentiment Assertio Positive AEON Biopharma Neutral Do analysts rate ASRT or AEON? Assertio presently has a consensus price target of $3.44, suggesting a potential upside of 164.42%. AEON Biopharma has a consensus price target of $5.00, suggesting a potential upside of 625.58%. Given AEON Biopharma's higher possible upside, analysts clearly believe AEON Biopharma is more favorable than Assertio.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Assertio 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00AEON Biopharma 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is ASRT or AEON more profitable? AEON Biopharma has a net margin of 0.00% compared to Assertio's net margin of -261.08%. Assertio's return on equity of 4.88% beat AEON Biopharma's return on equity.Company Net Margins Return on Equity Return on Assets Assertio-261.08% 4.88% 2.37% AEON Biopharma N/A N/A -240.45% Does the MarketBeat Community prefer ASRT or AEON? Assertio received 100 more outperform votes than AEON Biopharma when rated by MarketBeat users. However, 100.00% of users gave AEON Biopharma an outperform vote while only 59.44% of users gave Assertio an outperform vote. CompanyUnderperformOutperformAssertioOutperform Votes10759.44% Underperform Votes7340.56% AEON BiopharmaOutperform Votes7100.00% Underperform VotesNo Votes Which has more volatility & risk, ASRT or AEON? Assertio has a beta of 0.79, meaning that its stock price is 21% less volatile than the S&P 500. Comparatively, AEON Biopharma has a beta of 0.34, meaning that its stock price is 66% less volatile than the S&P 500. Which has higher earnings and valuation, ASRT or AEON? AEON Biopharma has lower revenue, but higher earnings than Assertio. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAssertio$132.19M0.94-$331.94M-$3.95-0.33AEON BiopharmaN/AN/A-$36.63MN/AN/A Do institutionals & insiders have more ownership in ASRT or AEON? 49.0% of Assertio shares are held by institutional investors. Comparatively, 22.8% of AEON Biopharma shares are held by institutional investors. 3.2% of Assertio shares are held by company insiders. Comparatively, 20.0% of AEON Biopharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. SummaryAssertio beats AEON Biopharma on 9 of the 14 factors compared between the two stocks. Ad Behind the MarketsOur #1 Ticker for the Rare "Retirement Window"We've only seen this happen three times in the past 20 years... And every time - like clockwork - it's minted an entire new class of millionaires.Click here for our #1 "Retirement Window" Stock >>> Get AEON Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for AEON and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding AEON and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat are MarkeBeat Followers?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AEON vs. The Competition Export to ExcelMetricAEON BiopharmaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$27.11M$7.53B$5.51B$8.43BDividend YieldN/A4.43%4.98%4.06%P/E RatioN/A18.73143.0418.91Price / SalesN/A357.761,700.1786.54Price / CashN/A37.6937.4331.50Price / Book-0.176.004.944.55Net Income-$36.63M$152.92M$115.12M$225.08M7 Day Performance-6.41%7.98%9.01%3.29%1 Month Performance-30.00%20.87%15.36%7.78%1 Year Performance-88.84%26.14%33.07%14.53% AEON Biopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ASRTAssertio2.605 of 5 stars2.61 / 5 stars$1.22-3.9%$3.44+181.8%-49.1%$116.05M$132.19M-0.3120Gap UpALXOALX Oncology3.9127 of 5 stars3.91 / 5 stars$2.22+3.7%$14.00+530.6%-56.3%$115.66MN/A-0.6040Short Interest ↑Positive NewsASMBAssembly Biosciences2.0801 of 5 stars2.08 / 5 stars$18.07+0.2%N/A+64.0%$114.74M$7.16M0.00100Analyst UpgradeGap UpFBLGFibroBiologics0.6784 of 5 stars0.68 / 5 stars$3.26+3.2%N/AN/A$114.62MN/A0.0010News CoverageGap UpVSTMVerastem2.2805 of 5 stars2.28 / 5 stars$2.81+1.4%$14.83+427.9%-70.2%$113.07M$2.60M-0.6450Gap UpSGMTSagimet Biosciences2.1441 of 5 stars2.14 / 5 stars$3.72+9.4%$24.00+545.2%-72.3%$113.06M$2M0.008CASICASI Pharmaceuticals3.4018 of 5 stars3.40 / 5 stars$7.17-0.7%$6.00-16.3%+219.0%$110.85M$33.88M-3.14180Gap DownPDSBPDS Biotechnology1.804 of 5 stars1.80 / 5 stars$3.00-1.6%$14.25+375.0%-39.9%$110.04MN/A-2.2120Analyst ForecastPYRGFPyroGenesis Canada0 of 5 stars0.00 / 5 stars$0.60+3.4%N/AN/A$109.92M$9.14M-5.4690Gap DownCYTTCyteir Therapeutics0 of 5 stars0.00 / 5 stars$3.01-0.3%N/AN/A$108.36MN/A-3.2046High Trading Volume Related Companies and Tools Related Companies: ASRT Alternatives ALXO Alternatives ASMB Alternatives FBLG Alternatives VSTM Alternatives SGMT Alternatives CASI Alternatives PDSB Alternatives PYRGF Alternatives CYTT Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:AEON) was last updated on 9/20/2024 by MarketBeat.com Staff From Our PartnersTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredTrump’s “Tax Free” Retirement StrategySince 1924 — over one hundred years — the US dollar has lost nearly 18x its value. If you're planning on re...Gold Safe Exchange | SponsoredThe election trade you can't losePolitics is an unpredictable game. But no matter what happens in the next few months... There's one thin...Investors Alley | SponsoredAre You Ready for a Small-Cap Rally?Jeff Bezos has just made a bold move into Quantum Computing as a Service (QaaS), a technology set to disrupt i...InvestorPlace | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredMust-Know for Trading OptionsOptions are becoming increasingly popular among investors – with demand hitting record highs for 3 years in a ...Unstoppable Prosperity | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredUnlock the Secret to Easy Wins with Iron CondorsDiscover the power of Iron Condor trades – a low-risk, high-reward strategy that allows you to profit consiste...Netpicks | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AEON Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share AEON Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free AEON Stock Alerts